The scope for pneumococcal vaccines that do not prevent transmission

Area of Science:

• Vaccinology
• Infectious Disease Epidemiology
• Public Health

Background:

• Pneumococcal conjugate vaccines (PCVs) significantly reduce pneumococcal disease, relying on herd protection for broad impact.
• Herd protection, or indirect protection of unvaccinated individuals, is crucial for disease elimination strategies.
• The development of new pneumococcal vaccines aims to prevent a majority of pneumococcal diseases.

Purpose of the Study:

• To assess the potential impact of a hypothetical pneumococcal vaccine candidate (HPVC) with high clinical efficacy but lacking herd protection.
• To compare the impact of HPVC with current PCVs, particularly in settings with high pediatric pneumococcal disease burden.

Main Methods:

• Modeling the impact of a hypothetical pneumococcal vaccine candidate (HPVC) with defined efficacy and lack of indirect protection.
• Comparing the projected disease reduction in young children and unvaccinated populations under HPVC and current PCV strategies.

Main Results:

• The hypothetical pneumococcal vaccine candidate (HPVC) demonstrated similar or superior impact among young children compared to current PCVs.
• HPVC use in infancy did not significantly impact unvaccinated individuals, unlike PCVs which provide herd protection.
• The study suggests HPVC could be a more affordable alternative, especially in regions where pneumococcal disease is concentrated in children.

Conclusions:

• A pneumococcal vaccine with high direct efficacy but no herd protection can still achieve substantial public health benefits in pediatric populations.
• HPVC represents a potentially cost-effective strategy for pneumococcal disease control, particularly in resource-limited settings.
• Future vaccine development should consider direct efficacy and targeted impact in high-burden populations.